Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Jing Huang, Jianming Xu, Yun Chen, +44

The Lancet Oncology

Esophageal CancerGastrointestinal OncologyMedicineClinical TrialsPathology +8

Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial

Kuimin Mei, Shukui Qin, Zhendong Chen, +3

Journal for ImmunoTherapy of Cancer

Comparison of Current Diagnostic Criteria for Acute-On-Chronic Liver Failure

Qian Zhang, Ying Li, Tao Han, +4

PLoS ONE

Heterogeneity of Hepatic Stellate Cells in Fibrogenesis of the Liver: Insights from Single-Cell Transcriptomic Analysis in Liver Injury

Wenjun Zhang, Simon J. Conway, Ying Liu, +12

Cells

Osteopontin promotes collagen I synthesis in hepatic stellate cells by miRNA-129-5p inhibition

Yinghua Chen, Yitao Ou, Jiale Dong, +7

Experimental Cell Research

FibrosisDevelopmental BiologyHepatic Stellate CellsMirna-129-5p InhibitionMatrix Biology +4

First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study

Ying Liu, Han Yue, Shuning Xu, +5

International Journal of Clinical Oncology

HepatologyMedicinePathologyCancer TreatmentOncology +5

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study

Hui Li, Shukui Qin, Ying Liu, +8

Drug Design Development and Therapy

Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization

Yuewei Zhang, Ao Jin, Ying Liu, +5

Tumor Biology

CT radiomics combined with clinical variables for predicting the overall survival of hepatocellular carcinoma patients after hepatectomy

Ying Liu, Xiaoqin Wei, Xinrui Zhang, +3

Translational Oncology

Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study

Chenyu Mao, Anwen Xiong, Jiong Qian, +11

Journal of Hematology & Oncology